Latest Novo Nordisk A/S (NVO) Headlines Diabete
Post# of 83
Posted On: 03/14/2014 6:40:07 PM
Latest Novo Nordisk A/S (NVO) Headlines
Diabetes: Herbal Bioactive Molecules Vs. Pharmaceutical Drugs - Volume 1: Cinnamon Global Markets, Competitors And Opportunities - 2014-2019 Analysis And Forecasts
M2 - Fri Mar 14, 10:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b4bhvn/diabetes_herbal) has announced the addition of the Diabetes: Herbal Bioactive Molecules Vs. Pharmaceutical Drugs - Volume 1: Cinnamon Global Markets, Competitors And Opportunities - 2014-2019 Analysis And Forecasts report to their offering. Diabetes is a metabolic disorder arising mainly due to the fault in the production of insulin or mounting resistance to its action. In the case of Diabetes, the most serious problem is the side effect, which occurs due to the accumulation of glucose. This excess glucose is converted into various compounds and also into free radicals, which damage the vital organs and organelles. Diabetes was seriously underrated as a threat to global public health until very recently. Today, Diabetes now ranks as one of the greatest public health challenges in the history of mankind. There were 382 million people with Diabetes, or 8.3% of the global population, in 2013. By 2035, this number will be 10.1%, equal almost 600 million people worldwide. Diabetes has a very large economic impact. For example, in the US the cost of diagnosed Diabetes in 2012 is estimated at US$245 billion, including $176 billion in direct medical costs. In 2013, the average Diabetes related expenditures per person in the US was USD9,800. Globally, per capita Diabetes related expenditures in 2013 was USD1,436. Further, the global market for Diabetes medications is estimated at approximately USD45 billion in 2013 and is growing 10.5% annually overall, with insulin sales increasing at a 14.2% CAGR. The currently available antidiabetic drugs manage the blood glucose levels under normal range by supplementing insulin, improving insulin sensitivity, increasing insulin secretion from the pancreas, decreasing glucose absorption from the intestinal tract and/or glucose uptake by tissue cells. Today, the management of Diabetes without any side effect is still a challenge to the medical fraternity. However, a wide array of plant-derived active principles has demonstrated antidiabetic activity. These natural medicines modulate blood sugar levels through a variety of mechanisms. In some cases their effects are similar to conventional medicines. This report looks at the use of medicinal plants, rather than pharmaceutical drugs, to both prevent and treat Diabetes. Specifically, it looks in detail at one of these plants: Cinnamon. Cinnamon is widely used and available and the market for it is well developed. The modern literature indicates that the potential antidiabetic properties of Cinnamon have been studied for over 20 years. Numerous trials have been conducted in humans to determine the metabolic effects of Cinnamon. This report provides: - A detailed look at the Diabetes market including its incidence by country now and during the next 20 years, economic impacts and costs by type, especially medications. - Analysis of medicinal plants to manage Diabetes including experimental studies on the hypoglycaemic activity and bioactive components of 66 plants. - The potential of Cinnamon for the management of Diabetes including its biological effects, molecular mechanisms of action and clinical studies. - Analysis of the global market for Cinnamon including production, imports, exports and traders. Additionally, profiles of 45 leading, public and private companies involved in the Cinnamon industry as producers, distributors, and retailers are given. The report also includes 30 tables and 50 figures. Key Topics Covered: CONTENTS EXECUTIVE SUMMARY INTRODUCTION Background Methodology and Sources Statistical Notes DIABETES MARKET OVERVIEW - Pandemic - Orthodox Approach - Lifestyle Changes - Diet - Nonorthodox Approach: Medicinal Plants - Global Economic Impact Of Diabetes - World Population Of 20-79 Year Olds: 2013-2035 - Diabetes Incidence By Country - Diabetes Prevalence By Country: 2013-2035 - Diabetes-Related Expenditure Per Person By Country: 2013-2035 - Economic Costs Of Diabetes In The US - US Diabetes Costs By Type - Diabetes Medications Company Market Shares - Insulin Is The Final Solution - Insulin Market Growth Drivers - Insulin Market Value Drivers - Insulin Market Growth: 2008-2013 - Insulin Market Growth By Region - Insulin Market Segments (Fast Acting, Premix, Long Acting) - GLP-1 MEDICINAL PLANTS AND DIABETES - Conventional Treatment - Conventional Antidiabetic Drugs - Medicinal Plants: A Safe Tool To Manage DM - Mechanism Of Action In Commonly Used Medicinal Plants - Pharmacologically Screened Insulinomimetic Or Insulin Secretagogues Plant Material And Phytoconstituents - Experimental Studies On Hypoglycaemic Activity And Bioactive Components Of 66 Plants - Acacia arabica - Aegle marmelos - Agrimony eupatoria - Allium sativum - Aloe vera - Annona muricata - Annona squamosa - Asparagus racemosus - Bauhinia variegata - Berberine - Biophytum sensitivum - Boerhaavia diffusa - Bougainvillea spectabilis - Brassica nigra - Caesalpinia bonducella - Caffeine - Camellia sinensis - Capsicum frutescens - Catharanthus roseus - Cinnamon zeylaniucm - Citrullus colocynthis - Coccinia indica - Cornus officinalis - Elephantopus scaber - Enicostemma littorale - Ephedra distachya - Eriobotrya japonica - Euccalyptus globulus - Eugenia jambolana - Ficus bengalensis - Fermented Unsalted Soybeans - Genistein - Ginkgo biloba - Radix glycyrrhizae - Gymnema sylvestre - Helicteres isora - Hibiscus rosa sinensis - Hordeum vulgare - Lepechinia caulescens - Medicago sativa - Momordica charantia - Mucuna pruriens - Nigella sativa oil - Panax ginseng - Pandanus odorus - Parinari excelsa - Prunella vulgaris - Psidium guajava - Pterocarpus marsupium - Radix rehmanniae - Rehmania glutinosa - Ricinus communis - Syzygium cumini - Salvia lavandifolia - Sarcopoterium spinosum - Selaginella tamariscina - Semen coicis - Smallanthus sonchifolius - Stevia rebaudiana - Swertia chirayita - Swertia punicea - Tabernanthe iboga - Teucrium polium - Tinospora crispa - Tribuluks terrestris - Trigonella foenum-graecum - Zizyphus spina-christi - Conclusions - Medicinal Plant Market - Production - Exports - Imports - Trade Balance CINNAMON AND DIABETES - Definition - Genus Cinnamomum - Species - Flavor, Aroma And Taste - History - Early History - Modern History - Agronomy Research And Development Efforts - Cultivation - Grading - Processing - Uses - Adverse Effects - Clinical Potential Of Cinnamon For The Management Of Diabetes - Biological Effects Of Cinnamon - Cinnamon Has Been Studied For Over 20 Years - Molecular Mechanisms Of Action Of Cinnamon - Clinical Studies With Cinnamon - Conclusions CINNAMON MARKET OVERVIEW - Cinnamon Vs. Medicinal Plant Production - Production - Cinnamon Market: 1992-2013 - Cinnamon Market Outlook: 2014-2019 - Cinnamon Exports By Country - Cinnamon Trade Balance By Country - Cinnamon Export And Import Companies COMPANY PROFILES A.A. Sayia & Company, Inc A. Baur & Co (Pvt.) Ltd. ACH Food Companies, Inc. Adam Group Adams Extract & Spice, LLC Ajinomoto Co., Inc. Bart Ingredients Company Ltd Bio Foods Pvt Ltd Bolner's Fiesta Products Ceylon Spice Company C.F. Sauer Company EOAS International Everson Spice Company First Spice Mixing Company Frontier Natural Products Co-op Inc. Goya Foods, Inc. HDDES Group Hong Son Cassia & Star Aniseed Processing Co., Ltd. Horn Company Huong Que Company Indus Organics Integrity Nutraceuticals International Founded Intercom Limited Ishana Spice Exports L B Spices Trading (Private) Limited La Flor Spices La India Packing Company McCormick & Company, Incorporated Monteray Bay Spice Company Mountain Rose Herbs Nature's Agro Products Lanka Company Novo Nordisk A/S Olam International Limited Orient Vietnam Company Limited PT Cassia Co-Op PT Dwiwarna Inti Sejahtera Rathna Producers Cinnamon Exports (Pvt) Ltd. Saboor Chatoor (Private) Limited SC Seasoning Co., Inc. SDS Spices (PVT) Ltd. Spice House USA The Empire Associates Tripper Vanns Spices Whole Foods Market, Inc. Wixon Inc. APPENDIX 1: DIABETES OVERVIEW - Classification - Insulin - Untreated Diabetes - Treated Diabetes - Poor Diagnosis Rates - Type 2 Medications - History - Type 1 Diabetes - Cause - Genetics - Environmental - Diet - Chemicals And Drugs - Pathophysiology - Diagnosis - Tight Glycaemic Control - Autoantibodies - Prevention - Immunosuppressive Drugs - Management - Pancreas Transplantation - Islet Cell Transplantation - Stem Cell Educator Therapy - Depression - Eating Disorders - Complications - Time Of Diagnosis - GAD65 Vaccine - T Helper Cell Shift - Labile Diabetes - Type 2 Diabetes - Signs and Symptoms - Complications - Cause - Lifestyle - Genetics - Medical Conditions - Pathophysiology - Diagnosis - Prevention - Management - Lifestyle - Medications - Surgery - Metabolic Syndrome - History - Definitions And Diagnosis - IDF - WHO - EGIR - NCEP - American Heart Association - Other - Etiology - Pathophysiology - Stress - Overweight And Obesity - Sedentary Lifestyle - Aging - Type 2 Risk - Coronary Heart Disease - Lipodystrophy - Psychiatric Illnesses - Rheumatic Diseases - Signs and Symptoms - Prevention - Therapy - Controversy - Diabetes And Food Prices APPENDIX 2: INSULIN OVERVIEW - Gene - Alleles - Regulation - Protein Structure - Synthesis - Release - Oscillations - Blood Content - Signal Transduction - Effect On Glucose Uptake and Metabolism - Degradation - Hypoglycemia - Diseases And Syndromes - Medication - Discovery - Extraction And Purification - Synthesis - Nobel Prizes - Glucagon-Like Peptide-1 - Physiological Functions - Leptin - Physiology - Function - Adiposity Signal - Interaction With Amylin - Metreleptin TABLES 1.) Global Diabetes Market Summary: 2014-2019 (Diabetes Cases (Million), Diabetes Related Expenditures Per Person (USD), Total Diabetes Related Expenditures (USD Billion), Total Diabetes Medications Demand (USD Billion), Medicinal Plants Production (USD Billion), Cinnamon Production (USD Million) 2.) Population Of 20-79 Year Olds Ranked For The World And 218 Countries Plus Growth Rates: 2013-2035 3.) Diabetes Cases (1000s) Among 20-79 Year Olds Ranked For The World And 218 Countries Plus Growth Rates: 2013-2035 4.) Diabetes National Prevalence (%) Ranked For The World And 218 Countries: 2013-2035 5.) Diabetes-Related Expenditures Per Person With Diabetes For The World And 218 Countries (USD): 2013 6.) US Health Care Expenditures By Diabetes Status And Type Of Service (USD Million): 2012 7.) US Health Care Expenditures Attributed To Diabetes By Age Group And Type Of Service (USD Million): 2012 8.) US Per Capita Health Care Expenditures Attributed To Diabetes By Age Group And Type Of Service (USD Million): 2012 9.) US Health Care Expenditures Attributed To Diabetes By Medical Condition And Type Of Service (USD Million): 2012 10.) US Annual Per Capita Health Care Expenditures By Diabetes Status (Actual Dollars): 2012 11.) Existing Synthetic Drugs For Type 2 DM In Market And Their Molecular Targets, Site Of Action And Adverse Reactions 12.) Commonly Used Conventional And Natural Medicines For Diabetes 13.) List Of Plants Having Antidiabetic Activity 14.) List of Plants Having Insulin Mimetic Or Insulin Secreatory Activity 15.) List Of Plants Phytoconstituents Having Insulin Secretagogues Or Insulin Mimetic Activity 16.) Global Medicinal Plant Exports By Country And Growth Rate (USD Thousands): 2008-2012 17.) Global Medicinal Plant Imports By Country And Growth Rate (USD Thousands): 2008-2012 18.) Global Medicinal Plant Trade Balance By Country And Growth Rate (USD Thousands): 2008-2012 19.) Summary Of Human Studies Where Patients With Type 2 Diabetes, Metabolic Syndrome, Impaired Fasting Glucose And Associated Diseases Were Treated With Cinnamon 20.) Global Medicinal Plant Vs. Cinnamon Production (USD Million): 2014-2019 21.) Global Cinnamon Production By Country (Metric Tons): 1982-2012 22.) Global Cinnamon Market (USD Million, Metric Tons, Average Selling Price): 1992-2013 23.) Global Cinnamon Market (USD Million, Metric Tons, Average Selling Price): 2014-2019 24.) Global Exports Of Cinnamon For World And 121 Countries (USD Thousand): 2008-2012 25.) Global Imports Of Cinnamon For World And 198 Countries (USD Thousand): 2008-2012 26.) Global Trade Balance Of Cinnamon For World And 202 Countries (USD Thousand): 2008-2012 27.) 481 Cinnamon Export Companies By Country (Name, Product/Service Categories Traded, Employees, Country, Website): 2014 28.) 201 Cinnamon Import Companies By Country (Name, Product/Service Categories Traded, Employees, Country, Website): 2014 29.) Comparison Of Type 1 And Type 2 Diabetes 30.) Commonly Prescribed Products For The Treatment Of Type 2 Diabetes FIGURES 1.) Global Diabetes Medications Market By Treatment Class (GLP-1, Insulin, OAD): 2003-2013 2.) Global Diabetes Medications Market Shares By Company (%): 2003-2013 3.) Progression Of Type 2 Diabetes And Treatment Intensification 4.) Distribution Of Patients And Value Across Treatment Classes 5.) Global Insulin Market Growth By Component: 2008-2013 6.) Global Insulin Market: Device Penetration Vs. Modern Insulin Penetration 7.) Global Modern Insulin Volume Company Market Shares 8.) Insulin Market Size And Growth By Region, Volume Composition, Volume Market Shares By Company: 2012-2013 9.) Regional (North America, Europe, China, Japan, Korea) Insulin Market Volume Growth Rates: 2003-2013 10.) Regional (North America, Europe, China, Japan, Korea) Insulin Volume Market Split: 2003-2013 11.) Action Profiles Of Insulins By Type 12.) Global Insulin Market Volume And Growth By Segment: 2008-2013 13.) Global GLP-1 Market Value And Market Share: 2008-2013 14.) GLP-1 Market By Region (%): 2013 15.) US GLP-1 Market-Victoza Vs. Other GLP-1(Value, TRx Scripts, % of Diabetes Care): 2010-2013 16.) Germany, UK And France Markets for GLP-1: Victoza Vs. Other GLP-1 Products (Value, % of Diabetes Care): 2009-2013 17.) Effects Of Phytochemicals in Insulin Secretion And Pancreatic--cell Apoptosis 18.) Cinnamomum verum 19.) Cinnamon Trees 20.) Cinnamon Products 21.) Flow Diagram Of Cinnamon Processing 22.) Mechanisms Of Action Of Cinnamon In Relevant Metabolic Pathways 23.) Novo Nordisk Diabetes Care Revenues By Segment (DKK Billion): 2013 24.) Novo Nordisk MAT Diabetes Care Sales Growth By Segment (%): 2008-2013 25.) Novo Nordisk Global And Regional Insulin Market Shares: 2013 26.) Novo Nordisk Revenue And Growth By Product and Region: 2009-2013 27.) Novo Nordisk Volume Market Share Across Insulin Classes 28.) Novo Nordisk Brand Names, Product Types, Sales, Market Shares, Patent Expirations: 2013 29.) Novo Nordisk's Modern Insulins Volume Market Share By Segment 30.) Novo Nordisk Product Growth And Market Shares By Segment: 2008-2013 31.) Novo Nordisk Modern Insulin US Market Share By Market Segment: 2008-2013 32.) US Insulin Supplier Volume Market Shares (%): 2013 33.) European Insulin Supplier Volume Market Shares (%): 2013 34.) Chinese Insulin Supplier Volume Market Shares (%): 2013 35.) Japanese Insulin Supplier Volume Market Shares (%): 2013 36.) Novo Nordisk Current And Future Product Portfolio 37.) Novo Nordisk R&D Pipeline: Diabetes And Obesity 38.) Insulin Secretion Profile 39.) Insulin Enables Glucose To Become Energy 40.) Insulin Level Vs. Time Of Day 41.) Diabetes Diagnosis And The Rule Of Halves 42.) Glycaemic Control In Selected Countries (%) 43.) Diabetes Prevalence And Diagnosis Rates By Region: 2013 44.) Main Symptoms of Diabetes 45.) Risk Reduction By Class From Lowering HbA1c By 1%-Point 46.) Insulin Synthesis Process 47.) Insulin Oscillations 48.) Idealized Diagram Of Blood Sugar Fluctuation 49.) Effect Of Insulin On Glucose Uptake And Metabolism 50.) The Structure Of Insulin Companies Mentioned: - A. Baur & Co (Pvt.) Ltd. - A.A. Sayia & Company, Inc - ACH Food Companies, Inc. - Adam Group - Adams Extract & Spice, LLC - Ajinomoto Co., Inc. - Bart Ingredients Company Ltd - Bio Foods Pvt Ltd - Bolner's Fiesta Products - C.F. Sauer Company - Ceylon Spice Company - EOAS International - Everson Spice Company - First Spice Mixing Company - Frontier Natural Products Co-op Inc. - Goya Foods, Inc. - HDDES Group - Hong Son Cassia & Star Aniseed Processing Co., Ltd. - Horn Company - Huong Que Company - Indus Organics - Integrity Nutraceuticals International Founded - Intercom Limited - Ishana Spice Exports - L B Spices Trading (Private) Limited - La Flor Spices - La India Packing Company - McCormick & Company, Incorporated - Monteray Bay Spice Company - Mountain Rose Herbs - Nature's Agro Products Lanka Company - Novo Nordisk A/S - Olam International Limited - Orient Vietnam Company Limited - PT Cassia Co-Op - PT Dwiwarna Inti Sejahtera - Rathna Producers Cinnamon Exports (Pvt) Ltd. - SC Seasoning Co., Inc. - SDS Spices (PVT) Ltd. - Saboor Chatoor (Private) Limited - Spice House USA - The Empire Associates - Tripper - Vanns Spices - Whole Foods Market, Inc. - Wixon Inc. For more information visit http://www.researchandmarkets.com/research/b4...tes_herbal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Investigation Report on China's Insulin Aspart Market to 2018
M2 - Fri Mar 14, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/52z4m8/investigation) has announced the addition of the "Investigation Report on China's Insulin Aspart Market, 2009-2018" report to their offering. According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with more than 380 million patients worldwide. On December 26, 2001 Novo Nordisk announced that the first insulin analogue insulin aspart (marketed by Novo Nordisk with the trade name ""Novorapid"") to treat insulin pump was approved by FDA. Insulin aspart was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analog, which was then harvested from a bioreactor. This analog has increased charge repulsion, which prevents the formation of hexamers, to create faster-acting insulin. Insulin aspart can reduce the level of postprandial glucose and glycated hemoglobin A (HbA1c). The onset of action is approximately 10 to 20 minutes. The global sales revenue of Novorapid in 2012 reached USD 2.78 billion, increased by 20% YOY. In April 2005, the first premixed insulin analogue Novomix 30 (composed of 30% soluble insulin aspart and 70% insulin aspart protamine) was launched in China. According to CRI's investigation on certain Chinese sample hospital market, the sales revenue of insulin aspart increased over 100 times from 2005 to 2013. Insulin aspart market in China is seized by Novo Nordisk. CRI's investigation also states that some Chinese enterprises are applying for production of the generic drug, which is expected to appear on the market no sooner than 2015. The number of diabetes patients as well as the market size of insulin aspart in China is predicted to increase in the next few years. Key Topics Covered: 1 Relevant Concepts of Insulin Aspart 2 Market Overview of Insulin Aspart in China 3 Investigation on Sales Value of Insulin Aspart in China, 2009-2013 4 Investigation on Market Share of Major Insulin Aspart Manufacturers in China, 2009-2013 5 Investigation on Market Size of Insulin Aspart by Dosage Form in China, 2009-2013 6 Reference Price Insulin Aspart in China Hospital Market, 2014 7 Major Manufacturing Enterprises in China Insulin Aspart Market, 2009-2013 8 Prospect of China Insulin Aspart Market, 2014-2018 For more information visit http://www.researchandmarkets.com/research/52...estigation
2014 Hormone Replacement Therapy Global Strategic Business Report - IMS Consensus Guidelines Paving Way for More Clarity of HRT
M2 - Thu Mar 13, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/657h9p/hormone) has announced the addition of the "Hormone Replacement Therapy (HRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Hormone Replacement Therapy (HRT) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS & ISSUES 4. COMPETITIVE LANDSCAPE 5. THERAPY PROFILE - A REVIEW OF SELECT RECENT STUDIES CONDUCTED - Researchers at Yale University Discover Discontinuation HRT May Lead to Premature Deaths - Bioidenticals versus Synthetic Hormone Replacement Therapy Agents - Studies at University of Sydney Researchers Reveal the Safety of Short-Term Unopposed Estrogens - US Researchers Reveal HRT Risks May be Dependent on Weight and Other Factors - Studies Prove HRT to Lower Risk of Pancreatic Cancer - University of Texas Reveal HRT Linked to Risks of Kidney Stones - Researchers at the Sundsvall Hospital Demonstrate Increased Incidence of Cataract Development in Women Undergoing HRT - Researchers at University of Southern California Demonstrate Estrogen Replacement Therapies Lower Stress Levels in Older Women - Studies at Uppsala University Hospital Demonstrate HRT is Associated with Improved Muscle Functioning in Postmenopausal women - Finnish Study Reveals HRT Usage Assist in the Treatment of Hot Flashes in Post Menopausal Women - Researchers at Johns Hopkins University Demonstrate Women Undergoing Hormone Therapy Less Prone to Alzheimer's Disease - French Study Reveals Hormone Replacement Pills May Affect Gall Bladder - Danish Studies Proves HRT Lowers Risk of Heart Attack and Heart Failure 6. PRODUCT OVERVIEW 7. PRODUCT INTRODUCTIONS/APPROVALS - Pfizer Receives FDA Approval for DUAVEE for Treatment of Vasomotor Symptoms - Noven Pharmaceuticals Launches Brisdelle Capsules - Lawley Pharmaceuticals Launches Profeme progesterone Bioidentical Hormone Replacement Cream - Bayer Receives FDA Approval for Low-Dose ANGELIQ? Tablets - Noven Pharmaceuticals Receives USFDA Approval for Minivelle - Mylan Pharmaceuticals Introduces Letrozole Tablets - Novo Nordisk Unveils Vagifem? 10?g - Amgen Obtains FDA Approval for Prolia in Treating Postmenopausal Women at Greater Risk of Osteoporosis 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 40 companies including many key and niche players such as: - Abbott Laboratories - AbbVie - Actavis - Bayer Pharma - Bayer Pharma's Hormone Replacement Therapy Product Pipeline - Hisamitsu Pharmaceutical - Noven Pharmaceuticals - Merck Sharp & Dohme - Novartis - Novo Nordisk - Orion - Pfizer - Rottapharm Madaus - Teva Pharmaceutical Industries - TherapeuticsMD - Upsher-Smith Laboratories For more information visit http://www.researchandmarkets.com/research/657h9p/hormone About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Global Insulin Delivery Devices Market is Expected to Grow at a CAGR of 8.5% During 2012-2017
M2 - Tue Mar 11, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rppmnp/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Forecast to 2017" report to their offering. 371 Million people had diabetes in 2012 and by 2030 this number is expected to rise to 552 Million. This finding by International Diabetes Federation (IDF) and similar results from studies done by organizations of repute like WHO, CDC, NHS etc. suggest that a huge patient population exists for the diabetes healthcare market. It is estimated that in 2011, around US$ 465 Billion were spent on healthcare expenditures related to diabetes. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of this current study. In latest research study, Global Insulin Delivery Devices Market Forecast to 2017, the company's analysts identified market dynamics in various important regions to highlight the areas offering promising possibilities for companies to boost their growth. The market, which stood at US$ 8.8 Billion in 2012, is expected to grow at a CAGR of 8.5% during 2012-2017. Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of delivery devices' market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment's growth and its future outlook. This study leads to the proposition that innovation has huge scope in this field and its analysts have advertently elaborated some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche, Becton, Dickinson and Company that together account for more than 90% of the global market. Companies Mentioned: - Novo Nordisk - Eli Lilly - Medtronic - Becton Dickinson - Sanofi-Aventis - F. Hoffmann La Roche For more information visit http://www.researchandmarkets.com/research/rp...al_insulin About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
New Diagnostic Test From Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 10:30AM CDT
Roche recently announced that its new diagnostic test, Elecsys Syphilis immunoassay, is now available in the markets.
The US Specialty Pharmaceutical Market Report: 2013 Edition
M2 - Tue Mar 11, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8bkqqb/the_us_specialty) has announced the addition of the "The US Specialty Pharmaceutical Market Report: 2013 Edition" report to their offering. Specialty pharmaceuticals are defined as a new, rapidly growing drugs and biologics that are manufactured as a result of continued advancements in drug technology and design. These pharmaceuticals are specialized, high cost products which can be difficult to administer and may require patient monitoring. Specialty pharmaceuticals are utilized as complex therapies for complex chronic diseases such as cancer, hemophilia, multiple sclerosis, HIV, hepatitis C, apart from others. Some of the specialized drugs that are used for treating such conditions meet all the three H's: High Cost, High Complexity and High Touch and they require extensive education for safe and cost-effective use. The specialty pharmaceuticals are mostly injectable or infused medicines but may also encompass oral medications. Specialty pharmacy is a special class of provider that are primarily responsible for distributing and dispensing the pharmaceutical as specialty pharmaceutical require specialized shipping and temperature-controlled storing and handling. Specialty pharmacy can be owned by stand-alone companies or large pharmacy chains. However, some drug wholesalers are also capable of shipping the specialty pharmaceuticals. There exists a substantial incentive for companies to research and develop products that address the unmet need of the patients as the specialty pharmaceutical market has the ability to sustain the high cost of these products thereby additionally offering a business perspective for the biopharmaceutical companies. The key factors driving growth of the US specialty pharmaceutical industry include accelerating US aging population, ameliorating economic condition, increased life expectancy, and increasing healthcare expenditure. Some of the noteworthy trends and developments of this industry include rising Medicare enrollment, novel specialty products in pipeline, conversion of patents to generic drugs, increased spending on specialty drugs and ongoing merger & acquisition activities. However, the growth of the industry is being hindered by lack of rigorous clinical trials, sluggish pace of innovation and inappropriate use of therapeutic drugs. The specialty pharmaceutical market witnesses fierce competition with numerous top notch players. The fierce competition prevailing in the US specialty pharmaceutical industry has been studied on a number of parameters such as competing drugs, mail pharmacies and distributors. Company profiles of leading players are also presented in the report. Key Topics Covered 1. Overview 1.1 Specialty Pharmaceuticals Vs Traditional Drugs 1.2 Applications of Specialty Pharmaceuticals 1.3 Specialty Pharmacy Services 1.4 Specialty Product Distribution 1.5 Specialty Pharma Manufacturer Services 1.6 Value Proposition of Specialty Pharmacy 2. Market Size 2.1 Pharmaceutical Market 2.2 The US Specialty Pharmaceutical Market 3. Market Dynamics 3.1 Growth Drivers 3.2 Trends and Developments 3.3 Challenges 4. Competitive Landscape 4.1 Competition by Drugs 4.2 Competition by Mail Pharmacy 4.3 Competition by Specialty Distributor 5. Company Profiles 6. Market Outlook 6.1 Market Forecast 6.2 Forecast Methodology Companies Mentioned - Amgen - Eli Lilly and Company - Johnson & Johnson - Novo Nordisk - Pfizer - Roche For more information visit http://www.researchandmarkets.com/research/8b..._specialty About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Caisson Biotech Expands HEPtune(TM) Drug Delivery Deal with Novo Nordisk
PR Newswire - Tue Mar 11, 4:30AM CDT
Caisson Biotech, L.L.C., a biopharmaceutical company with a patented heparosan-based drug delivery technology, HEPtune(TM), announced today that it has expanded the scope of its partnership with global healthcare leader Novo Nordisk A/S (NYSE: NVO). This latest license agreement gives Novo Nordisk 1) exclusive rights to commercialize insulin conjugated to HEPtune and 2) non-exclusive rights to leverage the HEPtune technology across other core therapeutic areas including other diabetes care products, human growth hormone therapy, treatments for obesity and for inflammatory diseases, such as Crohn's, lupus, rheumatoid and psoriatic arthritis.
Novo Nordisk Falls 1.36% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Mar 10, 5:36PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $46.56 to a high of $46.85. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $47.10 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Who Will Capture This $3.5 Billion Opportunity?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:30PM CDT
Two of the most highly successful compounds to win FDA approval in the past few years have been Regeneron's Eylea and Novartis ' and Roche 's Lucentis. Both drugs help improve vision in patients who are losing their sight due to age or...
Positive Data on Novartis' Jakavi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 3:50PM CDT
Novartis announced positive data from a phase III trial, RESPONSE, on blood cancer drug Jakavi.
Registration Now Open for Elite Life Science Career Fair
PR Newswire - Mon Mar 10, 11:43AM CDT
HireLifeScience.com, the premier career networking website for the Life Science industries, will host its 5th annual career fair at The NJ Convention and Exposition Center at Raritan Center in Edison, NJ on September 30, 2014, sponsored by Novo Nordisk. This marks the first time that Novo Nordisk will present their open positions at the annual hiring event. Additional event sponsors thus far include Covance. Some companies that will be returning for the event are Johnson & Johnson, LifeCell and Cubist Pharmaceuticals. More companies will be added during the spring and summer months.
Research and Markets: Global Hemophilia Market Report 2014-2018 with Baxter, Bayer, Novo Nordisk & Pfizer Dominating
Business Wire - Mon Mar 10, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw495w/global_hemophilia) has announced the addition of the "Global Hemophilia Market Report 2014-2018 with Baxter, Bayer, Novo Nordisk & Pfizer Dominating" report to their offering.
Global Hemophilia Market Report 2014-2018 with Baxter, Bayer, Novo Nordisk & Pfizer Dominating
M2 - Mon Mar 10, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7q98d5/global_hemophilia) has announced the addition of the "Global Hemophilia Market Report 2014-2018 with Baxter, Bayer, Novo Nordisk & Pfizer Dominating" report to their offering. Currently, most of the therapeutic hemophilia products are short acting, i.e., used only for when the patient suffers from bleeding. Further, many of these products exhibit immunogenic reactions resulting in a reduced effect of the therapeutic. In order to mitigate these issues, technologies such as PEGylation, recombinant DNA, and protein fusion technology, were developed and applied in the production of new therapies with a longer life span and fewer immunogenic reactions. For example, Biogen Idec is developing a next generation Hemophilia A therapy. The firm's leading therapeutic product, rFVIIIFc, is a recombinant - a truncated version of factor VIII, fused to the Fc domain of an antibody to extend half-life in the bloodstream. The resultant recombinant product is a result of Biogen's protein fusion technology. Thus, increase in technological innovations is expected to drive the Global Hemophilia market during the forecast period. According to the report, one of the major drivers in this market is the increase in the development of new hemophilia therapeutics. Currently, there are large number of products in the pipeline being developed by vendors which are aimed at addressing Hemophilia A, Hemophilia B, and von WilleBrand disease. The anticipated approval of these pipeline products is expected to contribute to the growth of the market during the forecast period. Further, the report states that one of the major challenges in this market is the high cost of hemophilia therapeutics. The high cost is attributed to the longer time taken to manufacture hemophilia prophylactics and manufacturing constraints. The key vendors dominating this market space are: - Baxter International Inc. - Bayer AG. - Novo Nordisk A/s-b. - Pfizer Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Hemophilia Product Pipeline 08. Market Segmentation of Hemophilia Market by Type 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7q...hemophilia
China Insulin Aspart & Lispro Market Investigation Reports Forecast to 2018 Now Available at ChinaMarketResearchReports.com
PRWeb - Mon Mar 10, 9:16AM CDT
According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with more than 380 million patients worldwide.
Novo Nordisk A/S - Share repurchase programme
GlobeNewswire - Mon Mar 10, 9:03AM CDT
On 30 January 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.
Pharma-Biotech Industry Helps Drive $14.4 Billion Industrial Project Activity in Massachusetts, an Industrial Info News Alert
Marketwire - Mon Mar 10, 5:30AM CDT
Researched by Industrial Info Resources (Sugar Land, Texas) -- Pharmaceutical manufacturing and bioscience activity is growing in Massachusetts. Five years ago, Bristol-Myers Squibb Company (NYSE:BMY) (New Brunswick, New Jersey) located its first plant in Devens, Massachusetts, north of Boston, and the company has big plans for the campus in the future. Other biotech firms are following suit.
Lilly Underwhelms Investors Again
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 09, 5:30PM CDT
Eli Lilly 's received bad news this week with the FDA opting against its SGLT-2 targeting diabetes drug empagliflozin. But what's really frustrating is that the FDA's denial wasn't tied to deficiencies in study sites, data presentation, or efficacy....
Label Expansion for Novartis' Xolair - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 4:30PM CST
Novartis received positive news when the European Commission (EC) approved Xolair for an additional indication.
Encouraging Data from Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:35PM CST
Roche (RHHBY) recently announced new encouraging data from phase IIb studies, LUTE / VERSE on asthma candidate lebrikizumab.
What Does This Rejection Mean for Eli Lilly?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 06, 1:00PM CST
In the extremely competitive world of Big Pharma, companies have to be careful to keep all of their ducks in neat little rows. I have made no secret of the fact that I believe Lilly struggles in that regard, and yesterday's surprising announcement...
Diabetes: Herbal Bioactive Molecules Vs. Pharmaceutical Drugs - Volume 1: Cinnamon Global Markets, Competitors And Opportunities - 2014-2019 Analysis And Forecasts
M2 - Fri Mar 14, 10:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b4bhvn/diabetes_herbal) has announced the addition of the Diabetes: Herbal Bioactive Molecules Vs. Pharmaceutical Drugs - Volume 1: Cinnamon Global Markets, Competitors And Opportunities - 2014-2019 Analysis And Forecasts report to their offering. Diabetes is a metabolic disorder arising mainly due to the fault in the production of insulin or mounting resistance to its action. In the case of Diabetes, the most serious problem is the side effect, which occurs due to the accumulation of glucose. This excess glucose is converted into various compounds and also into free radicals, which damage the vital organs and organelles. Diabetes was seriously underrated as a threat to global public health until very recently. Today, Diabetes now ranks as one of the greatest public health challenges in the history of mankind. There were 382 million people with Diabetes, or 8.3% of the global population, in 2013. By 2035, this number will be 10.1%, equal almost 600 million people worldwide. Diabetes has a very large economic impact. For example, in the US the cost of diagnosed Diabetes in 2012 is estimated at US$245 billion, including $176 billion in direct medical costs. In 2013, the average Diabetes related expenditures per person in the US was USD9,800. Globally, per capita Diabetes related expenditures in 2013 was USD1,436. Further, the global market for Diabetes medications is estimated at approximately USD45 billion in 2013 and is growing 10.5% annually overall, with insulin sales increasing at a 14.2% CAGR. The currently available antidiabetic drugs manage the blood glucose levels under normal range by supplementing insulin, improving insulin sensitivity, increasing insulin secretion from the pancreas, decreasing glucose absorption from the intestinal tract and/or glucose uptake by tissue cells. Today, the management of Diabetes without any side effect is still a challenge to the medical fraternity. However, a wide array of plant-derived active principles has demonstrated antidiabetic activity. These natural medicines modulate blood sugar levels through a variety of mechanisms. In some cases their effects are similar to conventional medicines. This report looks at the use of medicinal plants, rather than pharmaceutical drugs, to both prevent and treat Diabetes. Specifically, it looks in detail at one of these plants: Cinnamon. Cinnamon is widely used and available and the market for it is well developed. The modern literature indicates that the potential antidiabetic properties of Cinnamon have been studied for over 20 years. Numerous trials have been conducted in humans to determine the metabolic effects of Cinnamon. This report provides: - A detailed look at the Diabetes market including its incidence by country now and during the next 20 years, economic impacts and costs by type, especially medications. - Analysis of medicinal plants to manage Diabetes including experimental studies on the hypoglycaemic activity and bioactive components of 66 plants. - The potential of Cinnamon for the management of Diabetes including its biological effects, molecular mechanisms of action and clinical studies. - Analysis of the global market for Cinnamon including production, imports, exports and traders. Additionally, profiles of 45 leading, public and private companies involved in the Cinnamon industry as producers, distributors, and retailers are given. The report also includes 30 tables and 50 figures. Key Topics Covered: CONTENTS EXECUTIVE SUMMARY INTRODUCTION Background Methodology and Sources Statistical Notes DIABETES MARKET OVERVIEW - Pandemic - Orthodox Approach - Lifestyle Changes - Diet - Nonorthodox Approach: Medicinal Plants - Global Economic Impact Of Diabetes - World Population Of 20-79 Year Olds: 2013-2035 - Diabetes Incidence By Country - Diabetes Prevalence By Country: 2013-2035 - Diabetes-Related Expenditure Per Person By Country: 2013-2035 - Economic Costs Of Diabetes In The US - US Diabetes Costs By Type - Diabetes Medications Company Market Shares - Insulin Is The Final Solution - Insulin Market Growth Drivers - Insulin Market Value Drivers - Insulin Market Growth: 2008-2013 - Insulin Market Growth By Region - Insulin Market Segments (Fast Acting, Premix, Long Acting) - GLP-1 MEDICINAL PLANTS AND DIABETES - Conventional Treatment - Conventional Antidiabetic Drugs - Medicinal Plants: A Safe Tool To Manage DM - Mechanism Of Action In Commonly Used Medicinal Plants - Pharmacologically Screened Insulinomimetic Or Insulin Secretagogues Plant Material And Phytoconstituents - Experimental Studies On Hypoglycaemic Activity And Bioactive Components Of 66 Plants - Acacia arabica - Aegle marmelos - Agrimony eupatoria - Allium sativum - Aloe vera - Annona muricata - Annona squamosa - Asparagus racemosus - Bauhinia variegata - Berberine - Biophytum sensitivum - Boerhaavia diffusa - Bougainvillea spectabilis - Brassica nigra - Caesalpinia bonducella - Caffeine - Camellia sinensis - Capsicum frutescens - Catharanthus roseus - Cinnamon zeylaniucm - Citrullus colocynthis - Coccinia indica - Cornus officinalis - Elephantopus scaber - Enicostemma littorale - Ephedra distachya - Eriobotrya japonica - Euccalyptus globulus - Eugenia jambolana - Ficus bengalensis - Fermented Unsalted Soybeans - Genistein - Ginkgo biloba - Radix glycyrrhizae - Gymnema sylvestre - Helicteres isora - Hibiscus rosa sinensis - Hordeum vulgare - Lepechinia caulescens - Medicago sativa - Momordica charantia - Mucuna pruriens - Nigella sativa oil - Panax ginseng - Pandanus odorus - Parinari excelsa - Prunella vulgaris - Psidium guajava - Pterocarpus marsupium - Radix rehmanniae - Rehmania glutinosa - Ricinus communis - Syzygium cumini - Salvia lavandifolia - Sarcopoterium spinosum - Selaginella tamariscina - Semen coicis - Smallanthus sonchifolius - Stevia rebaudiana - Swertia chirayita - Swertia punicea - Tabernanthe iboga - Teucrium polium - Tinospora crispa - Tribuluks terrestris - Trigonella foenum-graecum - Zizyphus spina-christi - Conclusions - Medicinal Plant Market - Production - Exports - Imports - Trade Balance CINNAMON AND DIABETES - Definition - Genus Cinnamomum - Species - Flavor, Aroma And Taste - History - Early History - Modern History - Agronomy Research And Development Efforts - Cultivation - Grading - Processing - Uses - Adverse Effects - Clinical Potential Of Cinnamon For The Management Of Diabetes - Biological Effects Of Cinnamon - Cinnamon Has Been Studied For Over 20 Years - Molecular Mechanisms Of Action Of Cinnamon - Clinical Studies With Cinnamon - Conclusions CINNAMON MARKET OVERVIEW - Cinnamon Vs. Medicinal Plant Production - Production - Cinnamon Market: 1992-2013 - Cinnamon Market Outlook: 2014-2019 - Cinnamon Exports By Country - Cinnamon Trade Balance By Country - Cinnamon Export And Import Companies COMPANY PROFILES A.A. Sayia & Company, Inc A. Baur & Co (Pvt.) Ltd. ACH Food Companies, Inc. Adam Group Adams Extract & Spice, LLC Ajinomoto Co., Inc. Bart Ingredients Company Ltd Bio Foods Pvt Ltd Bolner's Fiesta Products Ceylon Spice Company C.F. Sauer Company EOAS International Everson Spice Company First Spice Mixing Company Frontier Natural Products Co-op Inc. Goya Foods, Inc. HDDES Group Hong Son Cassia & Star Aniseed Processing Co., Ltd. Horn Company Huong Que Company Indus Organics Integrity Nutraceuticals International Founded Intercom Limited Ishana Spice Exports L B Spices Trading (Private) Limited La Flor Spices La India Packing Company McCormick & Company, Incorporated Monteray Bay Spice Company Mountain Rose Herbs Nature's Agro Products Lanka Company Novo Nordisk A/S Olam International Limited Orient Vietnam Company Limited PT Cassia Co-Op PT Dwiwarna Inti Sejahtera Rathna Producers Cinnamon Exports (Pvt) Ltd. Saboor Chatoor (Private) Limited SC Seasoning Co., Inc. SDS Spices (PVT) Ltd. Spice House USA The Empire Associates Tripper Vanns Spices Whole Foods Market, Inc. Wixon Inc. APPENDIX 1: DIABETES OVERVIEW - Classification - Insulin - Untreated Diabetes - Treated Diabetes - Poor Diagnosis Rates - Type 2 Medications - History - Type 1 Diabetes - Cause - Genetics - Environmental - Diet - Chemicals And Drugs - Pathophysiology - Diagnosis - Tight Glycaemic Control - Autoantibodies - Prevention - Immunosuppressive Drugs - Management - Pancreas Transplantation - Islet Cell Transplantation - Stem Cell Educator Therapy - Depression - Eating Disorders - Complications - Time Of Diagnosis - GAD65 Vaccine - T Helper Cell Shift - Labile Diabetes - Type 2 Diabetes - Signs and Symptoms - Complications - Cause - Lifestyle - Genetics - Medical Conditions - Pathophysiology - Diagnosis - Prevention - Management - Lifestyle - Medications - Surgery - Metabolic Syndrome - History - Definitions And Diagnosis - IDF - WHO - EGIR - NCEP - American Heart Association - Other - Etiology - Pathophysiology - Stress - Overweight And Obesity - Sedentary Lifestyle - Aging - Type 2 Risk - Coronary Heart Disease - Lipodystrophy - Psychiatric Illnesses - Rheumatic Diseases - Signs and Symptoms - Prevention - Therapy - Controversy - Diabetes And Food Prices APPENDIX 2: INSULIN OVERVIEW - Gene - Alleles - Regulation - Protein Structure - Synthesis - Release - Oscillations - Blood Content - Signal Transduction - Effect On Glucose Uptake and Metabolism - Degradation - Hypoglycemia - Diseases And Syndromes - Medication - Discovery - Extraction And Purification - Synthesis - Nobel Prizes - Glucagon-Like Peptide-1 - Physiological Functions - Leptin - Physiology - Function - Adiposity Signal - Interaction With Amylin - Metreleptin TABLES 1.) Global Diabetes Market Summary: 2014-2019 (Diabetes Cases (Million), Diabetes Related Expenditures Per Person (USD), Total Diabetes Related Expenditures (USD Billion), Total Diabetes Medications Demand (USD Billion), Medicinal Plants Production (USD Billion), Cinnamon Production (USD Million) 2.) Population Of 20-79 Year Olds Ranked For The World And 218 Countries Plus Growth Rates: 2013-2035 3.) Diabetes Cases (1000s) Among 20-79 Year Olds Ranked For The World And 218 Countries Plus Growth Rates: 2013-2035 4.) Diabetes National Prevalence (%) Ranked For The World And 218 Countries: 2013-2035 5.) Diabetes-Related Expenditures Per Person With Diabetes For The World And 218 Countries (USD): 2013 6.) US Health Care Expenditures By Diabetes Status And Type Of Service (USD Million): 2012 7.) US Health Care Expenditures Attributed To Diabetes By Age Group And Type Of Service (USD Million): 2012 8.) US Per Capita Health Care Expenditures Attributed To Diabetes By Age Group And Type Of Service (USD Million): 2012 9.) US Health Care Expenditures Attributed To Diabetes By Medical Condition And Type Of Service (USD Million): 2012 10.) US Annual Per Capita Health Care Expenditures By Diabetes Status (Actual Dollars): 2012 11.) Existing Synthetic Drugs For Type 2 DM In Market And Their Molecular Targets, Site Of Action And Adverse Reactions 12.) Commonly Used Conventional And Natural Medicines For Diabetes 13.) List Of Plants Having Antidiabetic Activity 14.) List of Plants Having Insulin Mimetic Or Insulin Secreatory Activity 15.) List Of Plants Phytoconstituents Having Insulin Secretagogues Or Insulin Mimetic Activity 16.) Global Medicinal Plant Exports By Country And Growth Rate (USD Thousands): 2008-2012 17.) Global Medicinal Plant Imports By Country And Growth Rate (USD Thousands): 2008-2012 18.) Global Medicinal Plant Trade Balance By Country And Growth Rate (USD Thousands): 2008-2012 19.) Summary Of Human Studies Where Patients With Type 2 Diabetes, Metabolic Syndrome, Impaired Fasting Glucose And Associated Diseases Were Treated With Cinnamon 20.) Global Medicinal Plant Vs. Cinnamon Production (USD Million): 2014-2019 21.) Global Cinnamon Production By Country (Metric Tons): 1982-2012 22.) Global Cinnamon Market (USD Million, Metric Tons, Average Selling Price): 1992-2013 23.) Global Cinnamon Market (USD Million, Metric Tons, Average Selling Price): 2014-2019 24.) Global Exports Of Cinnamon For World And 121 Countries (USD Thousand): 2008-2012 25.) Global Imports Of Cinnamon For World And 198 Countries (USD Thousand): 2008-2012 26.) Global Trade Balance Of Cinnamon For World And 202 Countries (USD Thousand): 2008-2012 27.) 481 Cinnamon Export Companies By Country (Name, Product/Service Categories Traded, Employees, Country, Website): 2014 28.) 201 Cinnamon Import Companies By Country (Name, Product/Service Categories Traded, Employees, Country, Website): 2014 29.) Comparison Of Type 1 And Type 2 Diabetes 30.) Commonly Prescribed Products For The Treatment Of Type 2 Diabetes FIGURES 1.) Global Diabetes Medications Market By Treatment Class (GLP-1, Insulin, OAD): 2003-2013 2.) Global Diabetes Medications Market Shares By Company (%): 2003-2013 3.) Progression Of Type 2 Diabetes And Treatment Intensification 4.) Distribution Of Patients And Value Across Treatment Classes 5.) Global Insulin Market Growth By Component: 2008-2013 6.) Global Insulin Market: Device Penetration Vs. Modern Insulin Penetration 7.) Global Modern Insulin Volume Company Market Shares 8.) Insulin Market Size And Growth By Region, Volume Composition, Volume Market Shares By Company: 2012-2013 9.) Regional (North America, Europe, China, Japan, Korea) Insulin Market Volume Growth Rates: 2003-2013 10.) Regional (North America, Europe, China, Japan, Korea) Insulin Volume Market Split: 2003-2013 11.) Action Profiles Of Insulins By Type 12.) Global Insulin Market Volume And Growth By Segment: 2008-2013 13.) Global GLP-1 Market Value And Market Share: 2008-2013 14.) GLP-1 Market By Region (%): 2013 15.) US GLP-1 Market-Victoza Vs. Other GLP-1(Value, TRx Scripts, % of Diabetes Care): 2010-2013 16.) Germany, UK And France Markets for GLP-1: Victoza Vs. Other GLP-1 Products (Value, % of Diabetes Care): 2009-2013 17.) Effects Of Phytochemicals in Insulin Secretion And Pancreatic--cell Apoptosis 18.) Cinnamomum verum 19.) Cinnamon Trees 20.) Cinnamon Products 21.) Flow Diagram Of Cinnamon Processing 22.) Mechanisms Of Action Of Cinnamon In Relevant Metabolic Pathways 23.) Novo Nordisk Diabetes Care Revenues By Segment (DKK Billion): 2013 24.) Novo Nordisk MAT Diabetes Care Sales Growth By Segment (%): 2008-2013 25.) Novo Nordisk Global And Regional Insulin Market Shares: 2013 26.) Novo Nordisk Revenue And Growth By Product and Region: 2009-2013 27.) Novo Nordisk Volume Market Share Across Insulin Classes 28.) Novo Nordisk Brand Names, Product Types, Sales, Market Shares, Patent Expirations: 2013 29.) Novo Nordisk's Modern Insulins Volume Market Share By Segment 30.) Novo Nordisk Product Growth And Market Shares By Segment: 2008-2013 31.) Novo Nordisk Modern Insulin US Market Share By Market Segment: 2008-2013 32.) US Insulin Supplier Volume Market Shares (%): 2013 33.) European Insulin Supplier Volume Market Shares (%): 2013 34.) Chinese Insulin Supplier Volume Market Shares (%): 2013 35.) Japanese Insulin Supplier Volume Market Shares (%): 2013 36.) Novo Nordisk Current And Future Product Portfolio 37.) Novo Nordisk R&D Pipeline: Diabetes And Obesity 38.) Insulin Secretion Profile 39.) Insulin Enables Glucose To Become Energy 40.) Insulin Level Vs. Time Of Day 41.) Diabetes Diagnosis And The Rule Of Halves 42.) Glycaemic Control In Selected Countries (%) 43.) Diabetes Prevalence And Diagnosis Rates By Region: 2013 44.) Main Symptoms of Diabetes 45.) Risk Reduction By Class From Lowering HbA1c By 1%-Point 46.) Insulin Synthesis Process 47.) Insulin Oscillations 48.) Idealized Diagram Of Blood Sugar Fluctuation 49.) Effect Of Insulin On Glucose Uptake And Metabolism 50.) The Structure Of Insulin Companies Mentioned: - A. Baur & Co (Pvt.) Ltd. - A.A. Sayia & Company, Inc - ACH Food Companies, Inc. - Adam Group - Adams Extract & Spice, LLC - Ajinomoto Co., Inc. - Bart Ingredients Company Ltd - Bio Foods Pvt Ltd - Bolner's Fiesta Products - C.F. Sauer Company - Ceylon Spice Company - EOAS International - Everson Spice Company - First Spice Mixing Company - Frontier Natural Products Co-op Inc. - Goya Foods, Inc. - HDDES Group - Hong Son Cassia & Star Aniseed Processing Co., Ltd. - Horn Company - Huong Que Company - Indus Organics - Integrity Nutraceuticals International Founded - Intercom Limited - Ishana Spice Exports - L B Spices Trading (Private) Limited - La Flor Spices - La India Packing Company - McCormick & Company, Incorporated - Monteray Bay Spice Company - Mountain Rose Herbs - Nature's Agro Products Lanka Company - Novo Nordisk A/S - Olam International Limited - Orient Vietnam Company Limited - PT Cassia Co-Op - PT Dwiwarna Inti Sejahtera - Rathna Producers Cinnamon Exports (Pvt) Ltd. - SC Seasoning Co., Inc. - SDS Spices (PVT) Ltd. - Saboor Chatoor (Private) Limited - Spice House USA - The Empire Associates - Tripper - Vanns Spices - Whole Foods Market, Inc. - Wixon Inc. For more information visit http://www.researchandmarkets.com/research/b4...tes_herbal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Investigation Report on China's Insulin Aspart Market to 2018
M2 - Fri Mar 14, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/52z4m8/investigation) has announced the addition of the "Investigation Report on China's Insulin Aspart Market, 2009-2018" report to their offering. According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with more than 380 million patients worldwide. On December 26, 2001 Novo Nordisk announced that the first insulin analogue insulin aspart (marketed by Novo Nordisk with the trade name ""Novorapid"") to treat insulin pump was approved by FDA. Insulin aspart was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analog, which was then harvested from a bioreactor. This analog has increased charge repulsion, which prevents the formation of hexamers, to create faster-acting insulin. Insulin aspart can reduce the level of postprandial glucose and glycated hemoglobin A (HbA1c). The onset of action is approximately 10 to 20 minutes. The global sales revenue of Novorapid in 2012 reached USD 2.78 billion, increased by 20% YOY. In April 2005, the first premixed insulin analogue Novomix 30 (composed of 30% soluble insulin aspart and 70% insulin aspart protamine) was launched in China. According to CRI's investigation on certain Chinese sample hospital market, the sales revenue of insulin aspart increased over 100 times from 2005 to 2013. Insulin aspart market in China is seized by Novo Nordisk. CRI's investigation also states that some Chinese enterprises are applying for production of the generic drug, which is expected to appear on the market no sooner than 2015. The number of diabetes patients as well as the market size of insulin aspart in China is predicted to increase in the next few years. Key Topics Covered: 1 Relevant Concepts of Insulin Aspart 2 Market Overview of Insulin Aspart in China 3 Investigation on Sales Value of Insulin Aspart in China, 2009-2013 4 Investigation on Market Share of Major Insulin Aspart Manufacturers in China, 2009-2013 5 Investigation on Market Size of Insulin Aspart by Dosage Form in China, 2009-2013 6 Reference Price Insulin Aspart in China Hospital Market, 2014 7 Major Manufacturing Enterprises in China Insulin Aspart Market, 2009-2013 8 Prospect of China Insulin Aspart Market, 2014-2018 For more information visit http://www.researchandmarkets.com/research/52...estigation
2014 Hormone Replacement Therapy Global Strategic Business Report - IMS Consensus Guidelines Paving Way for More Clarity of HRT
M2 - Thu Mar 13, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/657h9p/hormone) has announced the addition of the "Hormone Replacement Therapy (HRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Hormone Replacement Therapy (HRT) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS & ISSUES 4. COMPETITIVE LANDSCAPE 5. THERAPY PROFILE - A REVIEW OF SELECT RECENT STUDIES CONDUCTED - Researchers at Yale University Discover Discontinuation HRT May Lead to Premature Deaths - Bioidenticals versus Synthetic Hormone Replacement Therapy Agents - Studies at University of Sydney Researchers Reveal the Safety of Short-Term Unopposed Estrogens - US Researchers Reveal HRT Risks May be Dependent on Weight and Other Factors - Studies Prove HRT to Lower Risk of Pancreatic Cancer - University of Texas Reveal HRT Linked to Risks of Kidney Stones - Researchers at the Sundsvall Hospital Demonstrate Increased Incidence of Cataract Development in Women Undergoing HRT - Researchers at University of Southern California Demonstrate Estrogen Replacement Therapies Lower Stress Levels in Older Women - Studies at Uppsala University Hospital Demonstrate HRT is Associated with Improved Muscle Functioning in Postmenopausal women - Finnish Study Reveals HRT Usage Assist in the Treatment of Hot Flashes in Post Menopausal Women - Researchers at Johns Hopkins University Demonstrate Women Undergoing Hormone Therapy Less Prone to Alzheimer's Disease - French Study Reveals Hormone Replacement Pills May Affect Gall Bladder - Danish Studies Proves HRT Lowers Risk of Heart Attack and Heart Failure 6. PRODUCT OVERVIEW 7. PRODUCT INTRODUCTIONS/APPROVALS - Pfizer Receives FDA Approval for DUAVEE for Treatment of Vasomotor Symptoms - Noven Pharmaceuticals Launches Brisdelle Capsules - Lawley Pharmaceuticals Launches Profeme progesterone Bioidentical Hormone Replacement Cream - Bayer Receives FDA Approval for Low-Dose ANGELIQ? Tablets - Noven Pharmaceuticals Receives USFDA Approval for Minivelle - Mylan Pharmaceuticals Introduces Letrozole Tablets - Novo Nordisk Unveils Vagifem? 10?g - Amgen Obtains FDA Approval for Prolia in Treating Postmenopausal Women at Greater Risk of Osteoporosis 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 40 companies including many key and niche players such as: - Abbott Laboratories - AbbVie - Actavis - Bayer Pharma - Bayer Pharma's Hormone Replacement Therapy Product Pipeline - Hisamitsu Pharmaceutical - Noven Pharmaceuticals - Merck Sharp & Dohme - Novartis - Novo Nordisk - Orion - Pfizer - Rottapharm Madaus - Teva Pharmaceutical Industries - TherapeuticsMD - Upsher-Smith Laboratories For more information visit http://www.researchandmarkets.com/research/657h9p/hormone About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Global Insulin Delivery Devices Market is Expected to Grow at a CAGR of 8.5% During 2012-2017
M2 - Tue Mar 11, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rppmnp/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Forecast to 2017" report to their offering. 371 Million people had diabetes in 2012 and by 2030 this number is expected to rise to 552 Million. This finding by International Diabetes Federation (IDF) and similar results from studies done by organizations of repute like WHO, CDC, NHS etc. suggest that a huge patient population exists for the diabetes healthcare market. It is estimated that in 2011, around US$ 465 Billion were spent on healthcare expenditures related to diabetes. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of this current study. In latest research study, Global Insulin Delivery Devices Market Forecast to 2017, the company's analysts identified market dynamics in various important regions to highlight the areas offering promising possibilities for companies to boost their growth. The market, which stood at US$ 8.8 Billion in 2012, is expected to grow at a CAGR of 8.5% during 2012-2017. Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of delivery devices' market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment's growth and its future outlook. This study leads to the proposition that innovation has huge scope in this field and its analysts have advertently elaborated some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche, Becton, Dickinson and Company that together account for more than 90% of the global market. Companies Mentioned: - Novo Nordisk - Eli Lilly - Medtronic - Becton Dickinson - Sanofi-Aventis - F. Hoffmann La Roche For more information visit http://www.researchandmarkets.com/research/rp...al_insulin About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
New Diagnostic Test From Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 10:30AM CDT
Roche recently announced that its new diagnostic test, Elecsys Syphilis immunoassay, is now available in the markets.
The US Specialty Pharmaceutical Market Report: 2013 Edition
M2 - Tue Mar 11, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8bkqqb/the_us_specialty) has announced the addition of the "The US Specialty Pharmaceutical Market Report: 2013 Edition" report to their offering. Specialty pharmaceuticals are defined as a new, rapidly growing drugs and biologics that are manufactured as a result of continued advancements in drug technology and design. These pharmaceuticals are specialized, high cost products which can be difficult to administer and may require patient monitoring. Specialty pharmaceuticals are utilized as complex therapies for complex chronic diseases such as cancer, hemophilia, multiple sclerosis, HIV, hepatitis C, apart from others. Some of the specialized drugs that are used for treating such conditions meet all the three H's: High Cost, High Complexity and High Touch and they require extensive education for safe and cost-effective use. The specialty pharmaceuticals are mostly injectable or infused medicines but may also encompass oral medications. Specialty pharmacy is a special class of provider that are primarily responsible for distributing and dispensing the pharmaceutical as specialty pharmaceutical require specialized shipping and temperature-controlled storing and handling. Specialty pharmacy can be owned by stand-alone companies or large pharmacy chains. However, some drug wholesalers are also capable of shipping the specialty pharmaceuticals. There exists a substantial incentive for companies to research and develop products that address the unmet need of the patients as the specialty pharmaceutical market has the ability to sustain the high cost of these products thereby additionally offering a business perspective for the biopharmaceutical companies. The key factors driving growth of the US specialty pharmaceutical industry include accelerating US aging population, ameliorating economic condition, increased life expectancy, and increasing healthcare expenditure. Some of the noteworthy trends and developments of this industry include rising Medicare enrollment, novel specialty products in pipeline, conversion of patents to generic drugs, increased spending on specialty drugs and ongoing merger & acquisition activities. However, the growth of the industry is being hindered by lack of rigorous clinical trials, sluggish pace of innovation and inappropriate use of therapeutic drugs. The specialty pharmaceutical market witnesses fierce competition with numerous top notch players. The fierce competition prevailing in the US specialty pharmaceutical industry has been studied on a number of parameters such as competing drugs, mail pharmacies and distributors. Company profiles of leading players are also presented in the report. Key Topics Covered 1. Overview 1.1 Specialty Pharmaceuticals Vs Traditional Drugs 1.2 Applications of Specialty Pharmaceuticals 1.3 Specialty Pharmacy Services 1.4 Specialty Product Distribution 1.5 Specialty Pharma Manufacturer Services 1.6 Value Proposition of Specialty Pharmacy 2. Market Size 2.1 Pharmaceutical Market 2.2 The US Specialty Pharmaceutical Market 3. Market Dynamics 3.1 Growth Drivers 3.2 Trends and Developments 3.3 Challenges 4. Competitive Landscape 4.1 Competition by Drugs 4.2 Competition by Mail Pharmacy 4.3 Competition by Specialty Distributor 5. Company Profiles 6. Market Outlook 6.1 Market Forecast 6.2 Forecast Methodology Companies Mentioned - Amgen - Eli Lilly and Company - Johnson & Johnson - Novo Nordisk - Pfizer - Roche For more information visit http://www.researchandmarkets.com/research/8b..._specialty About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Caisson Biotech Expands HEPtune(TM) Drug Delivery Deal with Novo Nordisk
PR Newswire - Tue Mar 11, 4:30AM CDT
Caisson Biotech, L.L.C., a biopharmaceutical company with a patented heparosan-based drug delivery technology, HEPtune(TM), announced today that it has expanded the scope of its partnership with global healthcare leader Novo Nordisk A/S (NYSE: NVO). This latest license agreement gives Novo Nordisk 1) exclusive rights to commercialize insulin conjugated to HEPtune and 2) non-exclusive rights to leverage the HEPtune technology across other core therapeutic areas including other diabetes care products, human growth hormone therapy, treatments for obesity and for inflammatory diseases, such as Crohn's, lupus, rheumatoid and psoriatic arthritis.
Novo Nordisk Falls 1.36% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Mar 10, 5:36PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $46.56 to a high of $46.85. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $47.10 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Who Will Capture This $3.5 Billion Opportunity?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:30PM CDT
Two of the most highly successful compounds to win FDA approval in the past few years have been Regeneron's Eylea and Novartis ' and Roche 's Lucentis. Both drugs help improve vision in patients who are losing their sight due to age or...
Positive Data on Novartis' Jakavi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 3:50PM CDT
Novartis announced positive data from a phase III trial, RESPONSE, on blood cancer drug Jakavi.
Registration Now Open for Elite Life Science Career Fair
PR Newswire - Mon Mar 10, 11:43AM CDT
HireLifeScience.com, the premier career networking website for the Life Science industries, will host its 5th annual career fair at The NJ Convention and Exposition Center at Raritan Center in Edison, NJ on September 30, 2014, sponsored by Novo Nordisk. This marks the first time that Novo Nordisk will present their open positions at the annual hiring event. Additional event sponsors thus far include Covance. Some companies that will be returning for the event are Johnson & Johnson, LifeCell and Cubist Pharmaceuticals. More companies will be added during the spring and summer months.
Research and Markets: Global Hemophilia Market Report 2014-2018 with Baxter, Bayer, Novo Nordisk & Pfizer Dominating
Business Wire - Mon Mar 10, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw495w/global_hemophilia) has announced the addition of the "Global Hemophilia Market Report 2014-2018 with Baxter, Bayer, Novo Nordisk & Pfizer Dominating" report to their offering.
Global Hemophilia Market Report 2014-2018 with Baxter, Bayer, Novo Nordisk & Pfizer Dominating
M2 - Mon Mar 10, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7q98d5/global_hemophilia) has announced the addition of the "Global Hemophilia Market Report 2014-2018 with Baxter, Bayer, Novo Nordisk & Pfizer Dominating" report to their offering. Currently, most of the therapeutic hemophilia products are short acting, i.e., used only for when the patient suffers from bleeding. Further, many of these products exhibit immunogenic reactions resulting in a reduced effect of the therapeutic. In order to mitigate these issues, technologies such as PEGylation, recombinant DNA, and protein fusion technology, were developed and applied in the production of new therapies with a longer life span and fewer immunogenic reactions. For example, Biogen Idec is developing a next generation Hemophilia A therapy. The firm's leading therapeutic product, rFVIIIFc, is a recombinant - a truncated version of factor VIII, fused to the Fc domain of an antibody to extend half-life in the bloodstream. The resultant recombinant product is a result of Biogen's protein fusion technology. Thus, increase in technological innovations is expected to drive the Global Hemophilia market during the forecast period. According to the report, one of the major drivers in this market is the increase in the development of new hemophilia therapeutics. Currently, there are large number of products in the pipeline being developed by vendors which are aimed at addressing Hemophilia A, Hemophilia B, and von WilleBrand disease. The anticipated approval of these pipeline products is expected to contribute to the growth of the market during the forecast period. Further, the report states that one of the major challenges in this market is the high cost of hemophilia therapeutics. The high cost is attributed to the longer time taken to manufacture hemophilia prophylactics and manufacturing constraints. The key vendors dominating this market space are: - Baxter International Inc. - Bayer AG. - Novo Nordisk A/s-b. - Pfizer Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Hemophilia Product Pipeline 08. Market Segmentation of Hemophilia Market by Type 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7q...hemophilia
China Insulin Aspart & Lispro Market Investigation Reports Forecast to 2018 Now Available at ChinaMarketResearchReports.com
PRWeb - Mon Mar 10, 9:16AM CDT
According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with more than 380 million patients worldwide.
Novo Nordisk A/S - Share repurchase programme
GlobeNewswire - Mon Mar 10, 9:03AM CDT
On 30 January 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.
Pharma-Biotech Industry Helps Drive $14.4 Billion Industrial Project Activity in Massachusetts, an Industrial Info News Alert
Marketwire - Mon Mar 10, 5:30AM CDT
Researched by Industrial Info Resources (Sugar Land, Texas) -- Pharmaceutical manufacturing and bioscience activity is growing in Massachusetts. Five years ago, Bristol-Myers Squibb Company (NYSE:BMY) (New Brunswick, New Jersey) located its first plant in Devens, Massachusetts, north of Boston, and the company has big plans for the campus in the future. Other biotech firms are following suit.
Lilly Underwhelms Investors Again
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 09, 5:30PM CDT
Eli Lilly 's received bad news this week with the FDA opting against its SGLT-2 targeting diabetes drug empagliflozin. But what's really frustrating is that the FDA's denial wasn't tied to deficiencies in study sites, data presentation, or efficacy....
Label Expansion for Novartis' Xolair - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 4:30PM CST
Novartis received positive news when the European Commission (EC) approved Xolair for an additional indication.
Encouraging Data from Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:35PM CST
Roche (RHHBY) recently announced new encouraging data from phase IIb studies, LUTE / VERSE on asthma candidate lebrikizumab.
What Does This Rejection Mean for Eli Lilly?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 06, 1:00PM CST
In the extremely competitive world of Big Pharma, companies have to be careful to keep all of their ducks in neat little rows. I have made no secret of the fact that I believe Lilly struggles in that regard, and yesterday's surprising announcement...
(0)
(0)Novo Nordisk A/S (NVO) Stock Research Links
Scroll down for more posts ▼